Background The development of a safe and effective vaccine against the human immunodeficiency
virus type 1 (HIV-1) is critical to pandemic control. Methods In a community-based, …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

The role of antibody in protection against human immunodeficiency virus (HIV-1) has been
difficult to study in animal models because most primary HIV-1 strains do not infect …

Dengue virus (DV), an arthropod-borne flavivirus, causes a febrile illness for which there is
no antiviral treatment and no vaccine 1, 2. Macrophages are important in dengue …

Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …

The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1)
eradication strategies 1 , 2 , 3 , 4 , 5 . However, it remains unclear when and where …

Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates
have typically shown post-infection virological control, but protection against acquisition of …

The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency
virus (HIV)-1 infection 1 . Antibodies against the HIV-1 envelope variable loops 1 and 2 (Env …